We carried out a systematic review of new drugs active in @entity1149 ( @entity1149 ). Fifty five phase II and III trials were reviewed ( @entity1206 (19 trials), @entity1311 (15), @entity136 (11), @entity1205 (6), @entity1945 (2) or @entity2600 (2)). The first four ones could be considered as active drugs when given as single agent. More information is required for the @entity9800 derivatives. Four phase III randomised studies were available, all concerning @entity1206 . They showed that in combination with @entity900 , @entity1206 improved the response rate and perhaps survival, in comparison to @entity1206 alone and that @entity1206 was better than 5 @entity1487 and @entity7324 . A quantitative overview was impracticable, because of too few randomised trials. A qualitative overview was carried out using the European Lung Cancer Working Party score. The overall median quality score was 65.3%. There was no statistically significant difference between the drugs, but there was a positive correlation between the score and the number of @entity1 . There was also an improvement of the quality score in favour of the randomised trials. Some important methodological aspects were often missing in the articles. In conclusion, @entity136 , @entity1206 , @entity1311 and @entity1205 are active against @entity1149 but more good-quality data are required to define their exact role in the routine.

Phase II and III studies with new drugs for XXXX : a systematic review of the literature with a methodology quality assessment.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan'] @entity7324 :: ('MESH:D014751', 'Chemical') :: ['vindesine'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung carcinoma'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel'] @entity1206 :: ('MESH:C030852', 'Chemical') :: ['vinorelbine'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity9800 :: ('MESH:D002166', 'Chemical') :: ['camptothecin'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity1945 :: ('MESH:D019772', 'Chemical') :: ['topotecan'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['fluorouracil']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']
